REG - Vulcan Two Group PLC - Notice of Results and Investor Presentation

Vulcan TwoAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260518:nRSR6137Ea&default-theme=true

RNS Number : 6137E  Vulcan Two Group PLC  18 May 2026

 

18 May 2026

Vulcan Two Group plc

(the "Company", "Group" or "Vulcan Two")

 

Notice of Results and Investor Presentation

 

Following the release of the Company's Full Year Results on Thursday 21 May
2026, the management team of Vulcan Two Group plc, the company aiming to
create the UK's leading regulated ePharmacy through buy-and-build, will be
hosting a live presentation at 12:30pm (BST) via the Investor Meet Company
platform.

 

Michael Kraftman (CEO), Keith Butcher (CFO) and Brendan O'Brien (COO) will
present an overview of the Company's vision, its proven buy-and-build
strategy, and the significant growth opportunity within the UK ePharmacy
market.

 

The presentation is open to all existing and potential shareholders and
registration can be completed via the following link:
www.investormeetcompany.com/vulcan-two-group-plc/register-investor
(//www.investormeetcompany.com/vulcan-two-group-plc/register-investor)

 

Questions can be submitted pre-event via your Investor Meet Company dashboard
up until 9:00am the day before the meeting or at any time during the live
presentation.

 

For further information please contact:

 

 Vulcan Two Group plc                                    Email: info@vulcantwo.com (mailto:info@vulcantwo.com)

 Michael Kraftman, Chief Executive Officer

 Keith Butcher, Chief Finance Officer

 Brendan O'Brien, Chief Operating Officer

 www.vulcantwo.com (http://www.vulcantwo.com)
 Canaccord Genuity Limited                               Tel: +44 (0) 20 7523 8000

(Nominated Adviser and Sole Broker)

 Simon Bridges / Harry Pardoe / Elizabeth Halley-Stott
 Alma Strategic Communications                           Email: vulcantwo@almastrategic.com (mailto:vulcantwo@almastrategic.com)

(Financial PR)

                                                       Tel: +44 (0) 20 3405 0205
 Justine James / Sam Modlin / Will Merison

 

Notes to Editors

Vulcan Two Group plc (AIM:VUL) is creating the UK's leading regulated
ePharmacy platform, through its disciplined buy-and-build strategy. Following
the acquisitions of CloudRx, Webmed and Hyperdrug in March 2026, the Group has
established a diversified, profitable platform spanning B2B prescription
fulfilment and B2C digital pharmacy services, with a high proportion of
recurring revenues and strong cash generation. Future growth is expected to be
supported through the acquisition of complementary businesses, expansion into
new sectors or markets, and investment in long-term assets.

The Group is led by an experienced management team with deep healthcare,
eCommerce and buy-and-build expertise.

For more information, visit www.vulcantwo.com (http://www.vulcantwo.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORSFUFSWEMSEII



            Copyright 2019 Regulatory News Service, all rights reserved